2018
Hating waiting
Tanovic E, Hajcak G, Joormann J. Hating waiting. Journal Of Experimental Psychopathology 2018, 9: 2043808718778982. DOI: 10.1177/2043808718778982.Peer-Reviewed Original ResearchLow-probability rewardForms of psychopathologyInhibitory intoleranceEmotion regulationGambling TaskNegative affectIndividual differencesDelay discountingLess willingnessPsychopathologyTaskGreater delayMore tensionWillingnessImpulsivityNeuroticismAffectDiscountingAnxietyRewardHigh levelsWaitersStudentsDifficultiesFindings
2014
Reducing Door‐to‐Puncture Times for Intra‐Arterial Stroke Therapy: A Pilot Quality Improvement Project
Mehta B, Leslie‐Mazwi T, Chandra R, Bell D, Sun C, Hirsch J, Rabinov J, Rost N, Schwamm L, Goldstein J, Levine W, Gupta R, Yoo A. Reducing Door‐to‐Puncture Times for Intra‐Arterial Stroke Therapy: A Pilot Quality Improvement Project. Journal Of The American Heart Association 2014, 3: e000963. PMID: 25389281, PMCID: PMC4338685, DOI: 10.1161/jaha.114.000963.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnesthesia Department, HospitalCooperative BehaviorFemaleFibrinolytic AgentsHumansInfusions, Intra-ArterialInterdisciplinary CommunicationMaleMiddle AgedPatient Care TeamPilot ProjectsProcess Assessment, Health CareProgram EvaluationPuncturesQuality ImprovementQuality Indicators, Health CareRetrospective StudiesStrokeThrombectomyThrombolytic TherapyTime and Motion StudiesTime FactorsTime-to-TreatmentTreatment OutcomeWorkflowConceptsPilot quality improvement projectQuality improvement projectPuncture timeMedian doorStroke patientsAnterior circulation stroke patientsIntra-arterial stroke therapyHospital time delayPre-QI cohortCompletion of imagingImprovement projectGreater delayNeurointerventional suiteHospital delayProximal occlusionIndependent predictorsStroke therapyPatient evaluationQI measuresWorse outcomesTherapy leadTreatment decisionsAnesthesia teamPatient arrivalPatients
1988
Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Hoey M, Kutt H, McDowell FH. Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1988, 11: 168. PMID: 3378225, DOI: 10.1097/00002826-198804000-00008.Peer-Reviewed Original ResearchConceptsSinemet CR4Parkinson's diseasePeak plasma levodopa concentrationResponse fluctuationsOpen-label studyAdvanced Parkinson's diseasePlasma levodopa concentrationsStandard SinemetInterdose intervalDaily dosesTherapeutic responseLevodopa concentrationsSame patientLabel studyDiseaseRelative bioavailabilityPatientsGreater delayTreatmentSinemetLevodopaDoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply